From a DFW toxicology lab MVP to a quantum-ready global precision medicine reimbursement platform — in six strategic phases across five continents.
Deploy V1.0 TARA and ToxIQ™ MVP. Stabilize the DFW toxicology and tox lab markets by automating retrospective appeals. Capitalize on Texas TRAIGA 36-month regulatory sandbox for speed advantage over out-of-state competitors.
Expand ToxIQ™ statewide to Houston, Austin, San Antonio, El Paso. Launch MolecuIQ™ for molecular & genomic diagnostics — NGS panels (81445/81455) and pharmacogenomics (CYP2C19/2D6) matched to NCCN/CPIC guidance, with MolDX compliance. Add PulmoIQ™ for pulmonary/respiratory reimbursement. Shift from retrospective appeals to upstream pre-submission prevention.
Full national rollout covering all 7 MAC jurisdictions. Launch ASC & Health Systems module and Epic/Cerner SMART-on-FHIR integrations. Shift from retrospective to real-time pre-submission prevention targeting 50% reduction in initial denial rates.
Canada: OHIP (Ontario), MSP (British Columbia), AHCIP (Alberta) private supplemental insurance denial intelligence. Mexico: IMSS/ISSSTE private payer adaptation — Mexico private healthcare growing at 25.1% CAGR with CDMX, Monterrey, Guadalajara as priority markets. Explore rare-disease navigation as an aspirational future research direction — not a current product.
Leverage QAOA and VQE to reformulate billing constraints into QUBO problems — calculating the absolute optimal CPT code combinations, modifiers, and clinical evidence across millions of evolving payer rule sets simultaneously. Grover's Algorithm provides quadratic speedups for fraud pattern detection.
We are raising a $3–7M seed round to fund Phase 1A and 1B execution. First revenue target: under 8 months.
